Pilot scheme for performance assessment of HIV-1 genotypic resistance testing in the UK.
HIV-1 drug susceptibility testing by genotypic methods is now widespread in the UK and it is thus important to determine the reproducibility of such investigations. A pilot study was carried out to determine the reproducibility between laboratories of genotypic testing by nucleotide sequencing of patient samples, and to compare the interpretations of the results provided to the clinicians. Samples were distributed between the participating laboratories. Eight laboratories, using three different methods, sequenced four samples. Nucleotide sequence and reports were collated and compared by one laboratory. Where sequencing data were obtained > 99% concordance was observed for nucleotide designations. No discordances in nucleotide sequencing were found in positions associated with drug resistance. However, there were considerable differences between the laboratories in the interpretation of some of the mutations with respect to their effect on drug susceptibility. This study emphasises the variability in the available interpretation systems, and the importance of joint laboratory-clinical discussion in making decisions about treatment options.
Cane
P A
PA
HPA Antiviral Susceptibility Reference Unit, Division of Immunity and Infection, University of Birmingham Medical School, Birmingham B15 2TT. p.cane@bham.ac.uk
Aitkin
C
C
Ward
K
K
Clarke
J
J
Parmar
S
S
Zuckerman
M
M
Smith
M
M
Tilston
P
P
O'Shea
S
S
Pillay
D
D
D003627:Data Interpretation, Statistical; D024882:Drug Resistance, Viral / Q000235:genetics*; D005838:Genotype; D015497:HIV-1 / Q000187:drug effects* / Q000235:genetics*; D006801:Humans; D007753:Laboratories / Q000592:standards; D010865:Pilot Projects; D015203:Reproducibility of Results; D017422:Sequence Analysis, DNA; D006113:United Kingdom